CDKN2A and neoplasm: Whole exome sequencing of tumor obtained at time of progressive disease did not reveal secondary BRAF or RAS mutations, but did demonstrate a somatic gain-of-function PIK3CA mutation (H1047R) as well as a CDKN2A aberration, which may have been responsible for dabrafenib resistance.